Decoding Bio (Substack)
Scaling Bio 008: Serif Biomedicines' Jake Rubens on Turning Modified DNA Into a New Class of Medicine
Why It Matters
DNA‑based medicines could fill the therapeutic gap between short‑lived mRNA drugs and permanent, costly gene therapies, offering a more flexible and accessible treatment option. As the biotech field seeks scalable, repeatable, and cell‑targeted modalities, Serif’s approach may accelerate the development of next‑generation genetic medicines and improve patient experiences, especially for complex diseases requiring precise, controllable dosing.
Key Takeaways
- •Modified DNA avoids immunity, reaches nucleus via cofactor protein
- •Lipid nanoparticles deliver DNA and mRNA cofactor for expression
- •Platform offers durable, redosable therapy bridging mRNA and gene therapy
- •AI accelerates DNA sequence and LNP optimization
- •Early animal data shows safety and strong expression
Pulse Analysis
Serif Biomedicines is positioning DNA as the next engineerable layer of biology, following the success of protein therapeutics and mRNA vaccines. By chemically modifying the DNA backbone and bases, the company silences innate immune detection while preserving coding capacity. A second breakthrough adds a short‑lived mRNA that translates a nuclear‑targeting cofactor protein, guiding the modified DNA into the cell nucleus. This two‑pronged strategy tackles the two historic roadblocks—immunogenicity and nuclear delivery—allowing DNA medicines to combine the durability of gene therapy with the flexibility of mRNA.
The therapeutic payload travels inside lipid nanoparticles, the same delivery vehicles that enabled COVID‑19 mRNA vaccines, but optimized specifically for DNA. Once inside the cytoplasm, the cofactor protein binds the DNA, enabling demodification and transcription into mRNA, which then produces the therapeutic protein. Serif’s preclinical work shows immune‑silent DNA is safe in non‑human primates and yields markedly longer expression than conventional mRNA in rodent models. AI‑driven design accelerates both DNA sequence engineering and high‑throughput LNP screening, creating data‑rich libraries that refine efficacy and tissue specificity.
Target selection balances technical feasibility, unmet medical need, and competitive differentiation. Serif is initially pursuing liver‑focused protein replacement and in‑vivo immune‑cell programming such as CAR‑T or CAR‑NK applications, where durable yet redosable expression offers a “Goldilocks” therapeutic window. The company plans to leverage strategic partnerships to expand its pipeline and manufacturing capacity, mirroring the growth paths of Genentech, Regeneron, and Moderna. If the platform delivers on its promise, modified DNA could reshape genetic medicine by providing scalable, repeatable treatments with fewer safety concerns than viral gene therapy.
Episode Description
A conversation on cracking the two barriers that have kept DNA out of the clinic, what the data shows in primates, and why the best solution might sit between mRNA and gene therapy
Comments
Want to join the conversation?
Loading comments...